Features | Partner Sites | Information | LinkXpress
Sign In
RANDOX LABORATORIES
GLOBETECH PUBLISHING
FOCUS DIAGNOSTICS, INC.

Blood Glucose Test Recommended for All Hospitalized Patients

By Labmedica International staff writers
Posted on 23 Jan 2012
It is recommended that all patients should have their blood glucose levels tested on admission to a hospital, irrespective of whether they have been diagnosed with diabetes or not.

Professional endocrinologists has released new clinical practice guidelines recommendations for practical and safe glycemic targets as well as offering protocols and system improvements needed to achieve glycemic goals for hospitalized patients in a noncritical care setting.

A team of experts, led by those at Emory University School of Medicine (Atlanta, GA, USA) have published a new guideline which contains consensus recommendations from experts in the field for the management of diabetes in hospitalized patients. Hyperglycemia, or high blood sugar (glucose) levels, is a common, serious and expensive healthcare problem in hospitalized patients that is linked to an increased risk of complications and mortality. It can also affect nondiabetic hospitalized patients. According to observational studies, 32% to 38% of patients in community hospitals suffer from hyperglycemia. Improving glycemic control leads to lower hospital complications in general medicine and surgery patients.

The recommendations include that most hospitalized patients with noncritical illness glycemic targets should have a premeal glucose target of less than 140 mg/dL and random blood glucose of less than 180 mg/dL. Also that all inpatients with known diabetes or with hyperglycemia of greater than 7.8 mmol/liter (140 mg/dL) be assessed with a hemoglobin A1C (HbA1C) level if this has not been performed in the preceding 2-3 months. Additional recommendations include a premeal glucose target of less than 140 mg/dL (7.8 mmol/liter) and a random blood glucose of less than 180 mg/dL (10.0 mmol/L) for the majority of hospitalized patients with noncritical illness. They recommend implementation of a standardized hospital-wide, nurse-initiated hypoglycemia treatment protocol to prompt immediate therapy of any recognized hypoglycemia, defined as blood glucose below 3.9 mmol/L (70 mg/dL).

The Clinical Practice Guideline (CPG) Program was established by The Endocrine Society (Chevy Chase, MD, USA). It provides endocrinologists and other clinicians with evidence-based recommendations for diagnosing and treating endocrine-related conditions. A consortium of topic-related endocrine experts creates each CPG recommendation based on scientific reviews of literature. The recommendations were published in the January 2012 issue of the Journal of Clinical Endocrinology & Metabolism (JCEM).

Related Links:
Emory University School of Medicine
The Endocrine Society



Sekisui Diagnostics
EUROIMMUN AG
PURITAN MEDICAL
comments powered by Disqus
Life Technologies

Channels

Pathology

view channel

New Approach Identifies Multiple Melanoma Drug Resistance Biomarkers

A recent paper described the use of liquid chromatography-multiple reaction monitoring mass spectrometry (LC-MRM) for assessing melanoma biomarkers in the blood in order to determine the effectiveness of chemotherapy. Modern chemotherapeutic techniques based on treatment with multiple anticancer drugs require the identification... Read more

Lab Technology

view channel
Image: Visualization from a numerical simulation of a cell flowing past the obstacle through the microfluidic device (Image courtesy of KTH – The Royal Institute of Technology).

Microfluidic Device Could Improve Biomarker Analyses

A new microfluidic device could offer a more reliable alternative for detecting biomarkers in patients facing such illnesses as cancer or malaria. The physical attributes of cells are important biomarkers... Read more

Industry News

view channel

IDT Acquires SURVEYOR Nuclease Product Line from Transgenomic

The SURVEYOR line is to be used by Integrated DNA Technologies (IDT; Coralville, IA, USA) primarily to support researchers performing mutation detection and potentially-clinical genome editing, and by Transgenomic, Inc. (Omaha, NE, USA) primarily to support diagnostic and other clinical applications. IDT, a world leader... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.